Selective matrix metalloproteinase (MMP) inhibitors in cancer therapy: ready for prime time?
about
The role of EMMPRIN in T cell biology and immunological diseasesThe interplay between the proteolytic, invasive, and adhesive domains of invadopodia and their roles in cancer invasionA systems biology view of blood vessel growth and remodellingThe behavior of matrix metalloproteinases and their inhibitors in colorectal cancerA novel MMP-2 inhibitor 3-azidowithaferin A (3-azidoWA) abrogates cancer cell invasion and angiogenesis by modulating extracellular Par-4Regulation of the basement membrane by epithelia generated forces.The High Mobility Group A1 (HMGA1) Transcriptome in Cancer and Development.The role of microRNAs in the pathogenesis of MMPi-induced skin fibrodysplasia.Stromal matrix metalloprotease-13 knockout alters Collagen I structure at the tumor-host interface and increases lung metastasis of C57BL/6 syngeneic E0771 mammary tumor cells.New strategies for targeting matrix metalloproteinasesMatrix metalloproteinase inhibition by heterotrimeric triple-helical Peptide transition state analoguesLive-cell imaging of tumor proteolysis: impact of cellular and non-cellular microenvironmentImmunohistochemical expression of MMP-2 and MMP-8 in oral squamous cell carcinoma.Glucosamine sulfate suppresses the expression of matrix metalloproteinase-3 in osteosarcoma cells in vitro.Cathepsin L targeting in cancer treatment.Active-site MMP-selective antibody inhibitors discovered from convex paratope synthetic libraries.Generation of inhibitory monoclonal antibodies targeting matrix metalloproteinase-14 by motif grafting and CDR optimization.Identification of highly selective MMP-14 inhibitory Fabs by deep sequencing.Functional cooperativity by direct interaction between PAK4 and MMP-2 in the regulation of anoikis resistance, migration and invasion in gliomaBreast tumor and stromal cell responses to TGF-β and hypoxia in matrix deposition.Potential clinical implications of recent matrix metalloproteinase inhibitor design strategiesOriginal Research: The expression of MMP2 and MMP9 in the hippocampus and cerebral cortex of newborn mice under maternal lead exposure.Interaction of stellate cells with pancreatic carcinoma cellsMonitoring and Inhibiting MT1-MMP during Cancer Initiation and Progression.Pigment epithelium-derived factor as a natural matrix metalloproteinase inhibitor: a comparison with classical matrix metalloproteinase inhibitors used for cancer treatment.STAT3: An Anti-Invasive Factor in Colorectal Cancer?New approaches to selectively target cancer-associated matrix metalloproteinase activity.In vivo optical imaging of MMP2 immuno protein antibody: tumor uptake is associated with MMP2 activitySynthesis and Evaluation of New Oxadiazole, Thiadiazole, and Triazole Derivatives as Potential Anticancer Agents Targeting MMP-9.Radiotherapy-induced gut toxicity: Involvement of matrix metalloproteinases and the intestinal microvasculature.Corticostriatal circuitry in regulating diseases characterized by intrusive thinking.Alendronate promotes plasmin-mediated MMP-9 inactivation by exposing cryptic plasmin degradation sites within the MMP-9 catalytic domain.The thiirane-based selective MT1-MMP/MMP2 inhibitor ND-322 reduces melanoma tumor growth and delays metastatic dissemination.Differentiation of prostate cancer cells using flexible fluorescent polymers.Arsenic trioxide inhibits invasion/migration in SGC-7901 cells by activating the reactive oxygen species-dependent cyclooxygenase-2/matrix metalloproteinase-2 pathway.The High Mobility Group A1 (HMGA1) gene is highly overexpressed in human uterine serous carcinomas and carcinosarcomas and drives Matrix Metalloproteinase-2 (MMP-2) in a subset of tumors.A study on quantitative structure-activity relationship and molecular docking of metalloproteinase inhibitors based on L-tyrosine scaffold.Constitutive K-RasG12D activation of ERK2 specifically regulates 3D invasion of human pancreatic cancer cells via MMP-1.New and paradoxical roles of matrix metalloproteinases in the tumor microenvironment.Development of a periplasmic FRET screening method for protease inhibitory antibodies.
P2860
Q26998829-7B292785-7D23-437D-96E8-8842C84F5262Q27003744-77ADE857-A166-4FF3-8FEA-C35292666EC5Q27003945-706611AF-F4E6-43C6-A70D-BC81ACA8CE90Q27004958-51A78D91-80DD-40C8-8629-4E670518B249Q27321296-AD343361-2168-446C-B166-75EFE32679ADQ30530312-D9E17F44-F86D-4CBF-8C71-421DB8DF9595Q33613335-B3FAF908-6A9A-4CC6-814A-B9872785694AQ34728974-110BAA50-2354-47FB-BBE8-74C73FDD24D6Q34980059-C3546B23-CD74-452F-A88E-65E49049A914Q35544060-E85B1D30-5A9D-41DC-814F-810225487A8EQ35557168-9E70FA3E-A6D4-475C-BE08-355D0FBF5F63Q35597185-90FBCDDD-FA67-43B6-9E28-AC44C6AA9B17Q35789632-4A276828-DAD6-470D-AAFB-4C3446BA2A26Q36113597-46C97268-4BED-4389-AEE2-E0CA95D76A4AQ36218199-6F42C562-6555-4C2C-ACB1-0E2D482A43E6Q36222825-BF5E44AB-FCAC-4D10-9905-85E19DDFB3D8Q36227084-75F0E5DE-F798-4B17-86E1-6AAFEA6139BBQ36250325-0BA1BBDC-8758-4E91-93DD-02E2532D0441Q36525192-93F87CB6-94EC-4871-810B-D64ABBA15C2DQ36736295-3E61C9DB-7BB6-48C7-9A18-1AA5BBCFC1CDQ36791870-62AA1648-BD18-401C-82B1-D99BFCC276F3Q37265405-C595A2CB-CA93-435B-92C7-840B89A5FF92Q37334274-9081CC1F-E4DB-4498-A41D-7A43C161D0D0Q37693503-F427FE2F-1F0F-410F-9B71-ECCC83BC0B7EQ38201795-51231513-92CC-4746-9A0D-6369B4E60B46Q38226312-19527734-3F14-4B25-B456-82DD674197C7Q38261141-6D767185-D525-4B07-BB14-481CF5CACBBEQ38672056-CE54C876-3B93-49B8-AEC9-147DB2A7DC87Q38698085-0D6FB7CF-CB43-4E63-B30F-4FA0CDF05D81Q38750934-A6831B08-8B0B-43F0-8A8F-0F791F4B2477Q38805967-5D18D204-9E4A-443D-98A4-7628805DCEB1Q39335249-ED10748D-BC86-4159-9A0E-B0FABBA807CCQ39336390-9ECF304E-8AEF-4199-8ADB-F4C46DF706DBQ39431900-42FAA494-A7DA-4FF7-8116-D30F0B7BCACDQ39548709-CD34FD59-3180-49F1-B299-5E26AB1FE735Q39899810-A5468F2F-F8C0-4426-9608-A6565E365BDDQ40385436-1B9F8420-77A2-46DA-9635-52A254194A62Q41903918-F8FD167E-4654-462B-B703-6CA35C9029EBQ42239363-D34AB35E-3B47-4CD0-A2D9-CCBBBCCE879AQ46033483-B924AFF8-53AA-4E65-AA76-6AEC2906E24D
P2860
Selective matrix metalloproteinase (MMP) inhibitors in cancer therapy: ready for prime time?
description
2009 nî lūn-bûn
@nan
2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Selective matrix metalloprotei ...... therapy: ready for prime time?
@ast
Selective matrix metalloprotei ...... therapy: ready for prime time?
@en
type
label
Selective matrix metalloprotei ...... therapy: ready for prime time?
@ast
Selective matrix metalloprotei ...... therapy: ready for prime time?
@en
prefLabel
Selective matrix metalloprotei ...... therapy: ready for prime time?
@ast
Selective matrix metalloprotei ...... therapy: ready for prime time?
@en
P2860
P356
P1476
Selective matrix metalloprotei ...... therapy: ready for prime time?
@en
P2093
Stanley Zucker
P2860
P304
P356
10.4161/CBT.8.24.10353
P577
2009-12-19T00:00:00Z